Inflammation-related biomarkers such as growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity-2 (sST2), Galectin-3 (Gal-3) and Galectin-9 (Gal-9) as well as hsCRP and IL-6, have been shown to predict new-onset HF and adverse CV events in HF patients [61–68] (Table 1). This evidence concerns the gene GDF15 and hydrops fetalis.